Eli Lilly and Co
Buyers have designed these 9 AI plays their main holdings, Financial institution of America facts reveals
Fund managers’ really like for synthetic intelligence-linked stocks has grown as lots of of these tech businesses have turn out to be their vital holdings in the portfolio, according to Lender of America’s investigation. The Wall Avenue firm seemed at the holdings of U.S. big-cap equity mutual funds that are actively managed. It screened the […]
Read More
This new weight loss drug ETF bets big on two of the industry’s leading players
ETF Edge This new weight loss drug ETF bets big on two of the industry’s leading players Published Mon, May 27 202412:01 PM EDT Anna Gleason@anna_gle WATCH LIVE Source
Read More
How digital health companies are capitalizing on the GLP-1 boom
Patent protection for Wegovy — Novo Nordisk’s blockbuster weight loss drug, which contains the second generation GLP-1 active ingredient and is at least twice as effective — is expected to expire by the decade’s end. Michael Siluk | UCG | Getty Images For Gray Beard, a kindergarten teacher in Charlotte, North Carolina, losing weight had […]
Read More
Eli Lilly to invest another $5.3 billion in Indiana plant to expand Mounjaro, Zepbound supply
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters Eli Lilly on Friday said it is investing another $5.3 billion in a manufacturing plant in Lebanon, Indiana to boost supply of its highly popular weight loss drug Zepbound, diabetes treatment […]
Read More
This up-and-coming cancer treatment could be a $25 billion market opportunity — it’s already a hotbed for M&A
Skynesher | E+ | Getty Images Big pharma is betting billions on an up-and-coming class of cancer treatments that some on Wall Street are calling a “massive opportunity.” It’s called targeted radiopharmaceutical therapy. It essentially delivers radiation directly into tumors by attaching a radioactive particle to a targeting molecule. RBC Capital Markets sees a $25 […]
Read More
A corner of the cancer therapy market is heating up—Here are the names investors need to know
There’s been a lot of attention lately on a corner of the oncology market called radiopharmaceuticals. The therapy seeks to destroy cancer cells by binding a radioactive particle to a targeted molecule and then dispatching it directly into the tumor. There are currently two products on the market from Novartis and a slew of clinical […]
Read More
Healthy Returns: Eli Lilly, Novo Nordisk are competing to develop more convenient weekly insulins
A patient injects herself with an insulin pen. Guido Krzikowski | Bloomberg | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! The rivalry between Eli Lilly and Novo Nordisk extends beyond a buzzy class of weight loss and diabetes drugs called GLP-1s. […]
Read More
JPMorgan states there is a new GLP-1 drug participant and its shares can rally 80%
Composition Therapeutics is an overlooked player in the GLP-1 current market, and could 1 working day boast a aggressive products and go up versus Eli Lilly and the like, according to JPMorgan. Analyst Hardik Parikh initiated research coverage on the clinical stage drug developer with an chubby rating and $65 value concentrate on, implying 82% […]
Read More
Eli Lilly stock hits new highs after a regulatory win in China. This is a big deal
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Tuesday’s key moments. The Nasdaq edged lower Tuesday, pulling back from record highs the session before. Jim Cramer described the market as overall “benign,” while the S & P 500 and Dow also […]
Read More
AstraZeneca targets $80 billion in total revenue by 2030 in ‘post-Covid era’
The Astrazeneca logo is pictured at the World Artificial Intelligence Conference 2021 in Shanghai, China, July 7, 2021. Costfoto | Future Publishing | Getty Images LONDON — Pharmaceutical company AstraZeneca on Tuesday said it planned to increase its total revenue to $80 billion by 2030 — up 75% from $45.8 billion in 2023. “We have […]
Read More